Benzinga | Oct 27, 2020 08:21AM EDT

Credit Suisse Maintains Outperform on Mirati Therapeutics, Raises Price Target to $225

Credit Suisse analyst Evan Seigerman maintains Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and raises the price target from $190 to $225.